Indication Discovery in vivo POC pre-IND Phase I
Pemphigus Vulgaris
TPM 203
Celiac Disease
TPM 501/502
Anti-drug immune responses
Uveitis, Cholangitis
Undisclosed, A-I
Undisclosed, A-I


Topas is utilizing its cutting-edge technology platform to develop a pipeline of novel therapies to treat autoimmune diseases, allergies and anti-drug antibodies.

  • Pemphigus vulgaris (PV): PV, an orphan disease, is an autoimmune condition where there is painful blistering on the skin and mucous membranes. While treatments are available to manage the condition, there is no cure. For this indication, there is already extensive knowledge about the related antigen, a validated biomarker and a clear and fast clinical phenotype (observable characteristics). Thus, it is an ideal area to demonstrate clinical proof-of-concept for the Topas Particle Conjugates (TPC) technology. TPM 203, Topas’ lead product candidate, is currently in a first-in-humans Phase 1 trial.
  • Celiac disease: Patients with celiac disease must avoid a wide variety of foods or suffer often severe stomach pain. Gluten is a well-described external antigen, making this a good area of focus for the TPC technology. Topas’ second product candidate, TPM501 is advancing towards the clinic for the treatment of celiac disease.
  • ADA-1: Topas is exploring a model system to prove successful projection of its approach towards the prevention of neutralizing antibodies generated against a marketed therapeutic. The program’s initial goal is to achieve pre-clinical proof-of-concept.